Lori Kunkel

Lori Anne Kunkel is currently an Independent Director at Oric Pharmaceuticals, Inc. since 2020, K36 Therapeutics, Inc. since 2020, and Enliven Therapeutics, Inc. since 2024.
Dr. Kunkel is also the Owner of Lak505, LLC since 2012.
Former roles include Independent Director at Curis, Inc. from 2016 to 2022; Director at Tocagen, Inc. from 2019 to 2020; Director at Loxo Oncology, Inc. from 2013 to 2019; Director at Amphivena Therapeutics, Inc.; Director at Maverick Therapeutics, Inc. from 2015 to 2021; Independent Director at Nurix Therapeutics, Inc. from 2019 to 2025; Director at Harpoon Therapeutics, Inc. from 2015 to 2016; Associate Director-Clinical Development at Chiron Corp.
from 1997 to 1998; Head-Clinical Scientist at Genentech, Inc. from 1998 to 2000; Chief Medical Officer at Pharmacyclics LLC from 2011 to 2013; Vice President-Medical Affairs at Genitope Corp.
from 2000 to 2003; Vice President-Clinical Development at Xencor, Inc. from 2005 to 2007; Chief Medical Officer at Syndax Pharmaceuticals, Inc. from 2009 to 2011; Chief Medical Officer at Proteolix, Inc. from 2007 to 2009; Chief Medical Officer at ACT Biotech, Inc. from 2010 to 2011; and Principal roles at Onyx Pharmaceuticals, Inc., XOMA Royalty Corp., ZymoGenetics, Inc., Salmedix, Inc., and DNAX Research, Inc. Dr. Kunkel was a Member of the Bone Marrow Transplant Unit at the University of California.
Education includes a doctorate from the University of Southern California and an undergraduate degree from the University of California San Diego.